<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079232</url>
  </required_header>
  <id_info>
    <org_study_id>1608015</org_study_id>
    <secondary_id>2016-A00319-42</secondary_id>
    <nct_id>NCT03079232</nct_id>
  </id_info>
  <brief_title>Optical Coherence Microscopy in Dermato-oncology</brief_title>
  <acronym>GALAXY</acronym>
  <official_title>In Vivo Imaging Innovation : Optical Coherence Microscopy in Dermato-oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DAMAE Médical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OCTAV is a medical device class I, not CE marked, based on a new technique for
      high-resolution imager (cell) internal microstructures of all types of biological tissues in
      vivo or ex vivo, to a depth of penetration 800 .mu.m. It allows to explore the epidermis, the
      dermo-epidermal junction and middle dermis in a totally non-invasive (direct contact with the
      tissue without sampling).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the coming of the patient in Dermatology for resection / biopsy of the tumor (usual
      practice), for the study, an image of the tumor will be performed with the OCTAV device
      (about 5 minutes) for the study. Then, according to usual practice, resection / biopsy will
      be performed.

      This study aims to validate the clinical relevance of this device to characterize the 3 main
      skin cancers and to obtain the necessary data for the implementation of future clinical
      trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity measures the proportion of positive skin cancers (according to the OCTAV device) that are correctly identified as such (according to gold standard : histology)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>Day 1</time_frame>
    <description>Specificity measures the proportion of negative skin cancers (according to the OCTAV device) that are correctly identified as such (according to gold standard : histology)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>OCTAV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCTAV</intervention_name>
    <description>In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.</description>
    <arm_group_label>OCTAV</arm_group_label>
    <other_name>OCTAV, DAMAE Medical, Paris, France</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a cutaneous lesion suspicious for melanoma, basal cell carcinoma,
             squamous cell carcinoma, requiring a surgical excision

          -  Consent form signed

        Exclusion Criteria:

          -  Allergy or intolerance to immersion oil (used for microscopy)

          -  If female, pregnant or breast-feeding

          -  Patient unable to stand still for 20 seconds

          -  Skin lesions located near patient eyes (&lt;3 cm)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc PERROT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT ETIENNE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cécile DUPONT, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>DAMAE Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Luc PERROT, MD</last_name>
    <phone>04 77 12 75 40</phone>
    <phone_ext>+33</phone_ext>
    <email>jeanluc.Perrot@univ-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnauld GARCIN, CRA</last_name>
    <phone>04 77 12 02 86</phone>
    <phone_ext>+33</phone_ext>
    <email>arnaud.garcin@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno LABEILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>jean-Luc PERROT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric CAMBAZARD, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Optical biopsy</keyword>
  <keyword>Skin cancer</keyword>
  <keyword>Diagnostic performance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

